Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-saharan african countries: Implications for second-line ART strategies

Clinical Infectious Diseases

Volumn 54, Issue 11, 2012, Pages 1660-1669

  Hamers, Raph L ^a,b,c   Sigaloff, Kim C E ^a,b,c   Wensing, Annemarie M ^d   Wallis, Carole L ^e   Kityo, Cissy ^f   Siwale, Margaret ^g   Mandaliya, Kishor ^h   Ive, Prudence ^e   Botes, Mariette E ⁱ   Wellington, Maureen ^j   Osibogun, Akin ^k   Stevens, Wendy S ^e   Rinke De Wit, Tobias F ^a,b,c   Schuurman, Rob ^d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^g Lusaka Trust Hospital   (Zambia)

^h Department of Obstetrics and Gynaecology   (Kenya)

ⁱ Muelmed Hospital   (South Africa)

^j Newlands Clinic   (Zimbabwe)

^k LAGOS UNIVERSITY TEACHING HOSPITAL   (Nigeria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; AFRICA; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NIGERIA; NONHUMAN; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; UGANDA; VIRUS LOAD; VIRUS RESISTANCE; ZAMBIA; ZIMBABWE;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

EID: 84861048505     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis254     Document Type: Article

References (45)

1. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-10.
2. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. 2010. Available at: http://www.who.int/hiv/pub/2010progressreport/report/en/index. html. Accessed 1 September 2011.
3. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:409-17.
4. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleo-side reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-34.
5. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23-31.
6. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46:1589-97.
7. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:480-4.
8. Johannessen A, Naman E, Kivuyo SL, et al. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis 2009; 9:108.
9. Wainberg MA, Zaharatos GJ, Brenner BG. Development of anti-retroviral drug resistance. N Engl J Med 2011; 365:637-46.
10. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011; 25:679-89.
11. Hamers RL, Oyomopito R, Kityo C, et al. Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific [published online ahead of print 21 April 2011]. Int J Epidemiol 2011.
12. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11:750-9.
13. Hamers RL, Schuurman R, Sigaloff KC, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study [published online ahead of print 27 October 2011]. Lancet Infect Dis 2011.
14. Myers RE, Gale CV, Harrison A, Takeuchi Y, Kellam P. A statistical model for HIV-1 sequence classification using the subtype analyser (STAR). Bioinformatics 2005; 21:3535-40.
15. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bio-informatics 2005; 21:3797-800.
16. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18:156-63.
17. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42:1608-18.
18. Wallis C, Papthanasopoulos M, Fox M, et al. Low rates of nucleoside reverse transcriptase inhibitor (NRTI) resistance detected in a well monitored cohort in South Africa accessing antiretroviral therapy [published online ahead of print 2 December 2011]. Antivir Ther 2011; doi:10.3851/IMP2010.
19. Hatano H, Hunt P, Weidler J, et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis 2006; 43:1329-36.
20. Cozzi-Lepri A, Phillips AN, Ruiz L, et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007; 21:721-32.
21. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of te-nofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
22. Margot NA, Lu B, Cheng A, Miller MD. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in study 903. HIV Med 2006; 7:442-50.
23. Parikh UM, Bacheler L, Koontz D, Mellors JW. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006; 80:4971-7.
24. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 2006; 50:4182-5.
25. Brenner BG, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006; 20:F9-13.
26. Coutsinos D, Invernizzi CF, Xu H, et al. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol 2009; 83:2029-33.
27. Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG, Wainberg M.A. Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis 2009; 200:1202-6.
28. Coutsinos D, Invernizzi CF, Xu H, Brenner BG, Wainberg M.A. Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1. Antivir Chem Chemother 2010; 20:117-31.
29. Coutsinos D, Invernizzi CF, Moisi D, et al. A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. PloS One 2011; 6:e20208.
30. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach 2010 revision. WHO: Geneva, Switzerland: 2010. Available at: http://whqlibdoc.who. int/publications/2010/9789241599764-eng.pdf. Accessed 1 October 2011.
31. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-60.
32. McComsey GA, Lo Re V 3rd, O'Riordan M, et al. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis 2008; 46:1290-6.
33. Bartlett J, Aga E, Ribaudo H, et al. A pilot study of LPV/r monotherapy following virologic failure of first-line NNRTI-containing regimens in resource-limited settings: the week-24 primary analysis of ACTG 5230. In: 18th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: CROI, 2011.
34. Hosseinipour MC, Kumwenda JJ, Weigel R, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med 2010; 11:510-8.
35. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, et al. Second-line anti-retroviral treatment successfully re-suppresses drug-resistant HIV-1 after first-line failure: prospective cohort in sub-Saharan Africa. J Infect Dis 2011; In press.
36. Pujades-Rodriguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA 2010; 304:303-12.
37. Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line an-tiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:500-6.
38. Murphy RA, Sunpath H, Lu Z, et al. Outcomes after virologic failure of first-line ART in South Africa. AIDS 2010; 24:1007-12.
39. Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etra-virine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies. AIDS 2010; 24:503-14.
40. Eshleman SH, Guay LA, Wang J, et al. Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr 2005; 40:24-9.
41. Eshleman SH, Hoover DR, Chen S, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005; 19:2167-9.
42. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005; 192: 30-6.
43. Kozal MJ, Chiarella J, St John EP, et al. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels. Antivir Ther 2011; 16:925-9.
44. Severe P, Juste MA, Ambroise A, et al. Early versus standard anti-retroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363:257-65.
45. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.